Aptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research note released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Price Performance

APVO opened at $0.34 on Friday. Aptevo Therapeutics has a fifty-two week low of $0.33 and a fifty-two week high of $33.67. The company’s 50-day moving average is $1.32 and its 200 day moving average is $73.61.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.